Welcome to the Oncology Brothers podcast! In this episode, we discussed the world of androgen receptor pathway inhibitors (ARPIs) in prostate cancer as part of our Tox Check series. Joined by esteemed guests Dr. Alicia Morgans, a GU medical oncologist from Dana-Farber Cancer Institute, and Dr. Christopher M. Pieczonka, a urologist from US Urology Partners, the discussion covered the common side effects associated with ARPIs, including cardiac issues, cognitive changes, and more.

Key topics included:

An overview of approved ARPIs, focusing on abiraterone, apalutamide, darolutamide, and enzalutamide
The importance of monitoring side effects and strategies to mitigate them
Insights from recent studies, highlighting the impact of these medications on patient quality of life
A discussion on the role of shared decision-making in treatment options for prostate cancer patients

Whether you're a healthcare professional or someone interested in prostate cancer treatment, this episode aims to equip you with valuable knowledge to better manage patient care.

Listen us on: Spotify: https://open.spotify.com/show/31BXhY9FM4gPWG10WgE11o

Follow us on social media: •⁠ ⁠X/Twitter: https://x.com/oncbrothers •⁠ ⁠Instagram: https://www.instagram.com/oncbrothers •⁠ Website: https://oncbrothers.com/

Don't forget to like, subscribe, and hit the notification bell for more insightful discussions from the Oncology Brothers!

#ProstateCancer, #ARPI, #SideEffectManagement, #SharedDecisionMaking, #OncologyBrothers

Managing Toxicities of Androgen Receptor Pathway Inhibitor (ARPI) in Prostate Cancer

Oncology Brothers: Practice-Changing Cancer Discussions

Managing Toxicities of Androgen Receptor Pathway Inhibitor (ARPI) in Prostate Cancer